Heron Therapeutics Strategy and Business Model

Executive Overview

Heron Therapeutics is a commercial-stage biotechnology company focused on two clinically important but operationally specific problems: managing pain around surgery and preventing nausea and vomiting associated with surgery and chemotherapy. Founded in 1983 and now headquartered in Cary, North Carolina, Heron sells four marketed products in the United States: ZYNRELEF and APONVIE in acute care, and CINVANTI and SUSTOL in oncology supportive care. The company competes in a narrow part of branded pharmaceuticals where success depends less on broad primary-care scale and more on formulary wins, protocol adoption, reimbursement support, and repeat use in hospitals, ambulatory surgery centers, and oncology clinics. As reflected in FY2024 and 2025 public communications, Heron’s strategy is to use a focused commercial infrastructure to grow its acute care franchise while maintaining and optimizing its oncology franchise, with a strong emphasis on operating discipline. Heron’s commercial footprint is primarily U.S.-based, and its model relies heavily on wholesalers, provider accounts, and outsourced manufacturing rather than owned plants or retail pharmacy scale. FY2024 net product sales were about $138 million, making Heron a relatively small but strategically focused specialty-pharma company.

Heron Therapeutics at a Glance

Logo
Common name	Heron Therapeutics
Full legal name	Heron Therapeutics, Inc.
Headquarters	Cary, North Carolina, United States
Ownership	Public company
Ticker	HRTX
Exchange	NASDAQ
Market Cap	$78.43M
Revenue (FY2024)	#N/A
Founding / major historical milestones	Founded in 1983; operated as A.P. Pharma before renaming to Heron Therapeutics in 2014; key FDA approvals include SUSTOL (2016), CINVANTI (2017), ZYNRELEF (2021), and APONVIE (2023).
Industry or industries	Biotechnology; branded pharmaceuticals; acute care and oncology supportive care
Key products or services	ZYNRELEF, APONVIE, CINVANTI, and SUSTOL
Geographic footprint	Primarily United States
Business segments as officially reported	One reportable segment; commercially managed across Acute Care and Oncology Care franchises
Company website	https://www.herontx.com/

1. What Is the Strategy of Heron Therapeutics?

Heron’s public filings and investor materials do not present its strategy in explicit “Playing to Win” language, but the company’s choices map clearly to that framework. In practice, Heron is trying to build a focused specialty-pharma business around hospital and clinic-administered products where differentiated formulations, targeted sales execution, and protocol adoption matter more than broad therapeutic breadth.

1. 1a. What is the winning aspiration of Heron Therapeutics?

   Heron’s winning aspiration appears to be to become a durable, self-sustaining branded pharmaceutical company in acute care and oncology supportive care by improving patient management at high-friction points in treatment: postsurgical pain, postoperative nausea and vomiting, and chemotherapy-induced nausea and vomiting. Public communications in FY2024 and 2025 suggest that “winning” is not defined as becoming a large diversified biotech; it is defined more narrowly as growing net product sales, expanding acute care adoption, maintaining the oncology franchise, and doing so with tighter operating discipline and a path toward sustained profitability.

2. 1b. Where does Heron Therapeutics play?

   Heron plays in U.S.-centric, provider-administered specialty pharmaceuticals. Its target settings are hospitals, ambulatory surgery centers, perioperative departments, and oncology infusion environments. It focuses on products that sit inside treatment protocols rather than chronic retail-prescription markets. That means Heron is not trying to serve every prescriber or every therapeutic area; it is concentrating on acute care and oncology supportive care accounts where clinical workflow, formulary approval, and reimbursement matter disproportionately.

3. 1c. How does Heron Therapeutics plan to win?

   Heron’s “how to win” is based on differentiated formulations plus focused commercial execution. ZYNRELEF is positioned as a branded non-opioid postsurgical analgesia option in selected procedures, while APONVIE, CINVANTI, and SUSTOL address nausea and vomiting in perioperative and oncology settings. The company is trying to win by offering clinically useful alternatives that can be embedded into care pathways, supported by a specialized sales force, formulary work, and targeted reimbursement support. In acute care, a key element of the strategy is that ZYNRELEF and APONVIE can be sold into overlapping hospital and ambulatory surgery center accounts, improving sales-force leverage. In oncology, Heron competes through protocol relevance, account penetration, and execution rather than scale.

4. 1d. What capabilities must Heron Therapeutics have in place?

   To make that strategy work, Heron needs a relatively specific set of capabilities: formulation and lifecycle-management expertise; regulatory, quality, and pharmacovigilance systems suitable for marketed pharmaceuticals; reliable contract manufacturing and supply planning; market access and contracting capabilities; and a specialty sales organization that can persuade hospitals, surgery centers, and oncology clinics to adopt products at the protocol level. It also needs strong medical affairs and health-economic messaging because customers are often evaluating not just efficacy, but workflow convenience, opioid-sparing potential, and budget impact.

5. 1e. What management systems does Heron Therapeutics require?

   Heron needs management systems that are more operationally rigorous than those of a typical early-stage biotech. These include account-level sales tracking, formulary-conversion metrics, demand forecasting, inventory management, quality oversight of third-party manufacturers, and disciplined control of selling, general, and administrative spending. Because the company is relatively concentrated by product and geography, management also needs tight cash management, supplier-risk monitoring, and rapid feedback loops between commercial execution and resource allocation.

2. What Are the Current Strategic Initiatives of Heron Therapeutics?

Based on FY2024 disclosures and 2025 management commentary, Heron’s current strategic initiatives are practical and commercially oriented rather than transformational.

• Expand ZYNRELEF adoption in acute care. Heron has been focused on converting broader clinical awareness into repeat account usage for ZYNRELEF, especially in procedures where non-opioid pain management and discharge efficiency matter. The practical work includes winning formulary access, targeting high-value procedures, and increasing utilization within existing accounts rather than simply opening new ones.
• Scale APONVIE through the same acute care infrastructure. APONVIE gives Heron a second product to sell into perioperative accounts. A clear strategic initiative is to use the existing acute care sales force and customer relationships to drive broader adoption, improving productivity per account and making the franchise more attractive to hospitals and ambulatory surgery centers.
• Maintain and optimize the oncology care franchise. CINVANTI and SUSTOL remain important revenue contributors. Heron’s public posture suggests a focus on defending these products through field execution, account retention, contracting, and clinical positioning in antiemetic regimens rather than treating them as passive legacy assets.
• Improve operating leverage. A recurring management priority has been commercial execution with tighter cost discipline. That means trying to grow revenue faster than operating expense, using one commercial organization across multiple products, and improving the efficiency of gross-to-net management, logistics, and overhead.
• Use evidence and education to support protocol adoption. In Heron’s markets, providers must often be convinced to change established practice patterns. Medical education, real-world evidence, and account-specific value communication therefore remain ongoing strategic initiatives, especially for acute care products where clinical workflow and reimbursement can influence adoption.

3. What Is the Business Model of Heron Therapeutics?

Heron’s business model is a focused branded-drug model built around provider-administered products rather than retail prescriptions or subscription revenue. The company sells units of four branded pharmaceuticals, almost all through U.S. healthcare channels.

• What customers actually buy: Hospitals, ambulatory surgery centers, oncology clinics, and related channel partners buy branded injectable or procedure-used pharmaceuticals intended for specific care settings. The end customer is not a consumer; it is a healthcare provider making a formulary or protocol decision.
• Recurring or repeat-driven versus one-time: The model is repeat-driven rather than contractually recurring. Once a product is adopted into a protocol or used routinely in a procedure or chemotherapy regimen, orders can recur with procedure volume or infusion volume. But there is no software-like subscription lock-in.
• How pricing power works: Pricing power exists only to the extent that Heron can demonstrate meaningful clinical or workflow value versus generics or alternative branded options. Because buyers are sophisticated and substitutes exist, realized pricing is shaped by contracting, chargebacks, government discounts, channel mix, and formulary economics.
• Why the business mix matters: The mix between mature oncology products and newer acute care products matters a great deal. The oncology franchise has historically provided important revenue stability, while the acute care franchise is more central to Heron’s growth narrative. A better mix can improve scale and absorb fixed selling costs.
• What drives gross margin, operating margin, and cash generation: Gross margin depends on manufacturing yields, batch economics, product mix, and the cost of outsourced production and distribution. Operating margin depends heavily on whether product sales can cover a specialty commercial organization and public-company overhead. Cash generation is influenced by working capital discipline, inventory planning, and whether sales growth reduces the burden of fixed costs.
• Revenue model: This is a unit-sales pharmaceutical model. Revenue is recognized from product sales, net of rebates, chargebacks, returns, and other deductions. It is not a royalty-heavy or subscription-based model.

4. What Products and/or Services Does Heron Therapeutics Sell?

As of FY2024 and early 2025, Heron is essentially a four-brand commercial portfolio. It is a product company, not a services company.

Commercially, the portfolio breaks into two clusters. The acute care franchise consists of ZYNRELEF and APONVIE and is central to the company’s growth strategy. The oncology care franchise consists of CINVANTI and SUSTOL and appears to provide a more established revenue base. The most strategically important distinction is between mature products that support the operating base and newer products that must drive future scale.

5. What Are the Key Competitors or Peers of Heron Therapeutics?

Heron does not have a single company-wide competitor that mirrors its entire portfolio. Competition is therapy-specific and often fragmented. In acute care, the most visible branded rivalry is around surgical pain management; in supportive care, competition includes both branded and generic antiemetics.

• Pacira BioSciences — The closest branded comparator in postsurgical pain management. Pacira’s Exparel competes for anesthesiology and surgical protocol attention, budget, and clinical mindshare.
• Eagle Pharmaceuticals — Through the Barhemsys product family acquired with Acacia Pharma, Eagle is relevant in perioperative nausea and vomiting management and competes for hospital antiemetic positioning.
• Merck — Merck’s Emend franchise and related antiemetic options are established competitors in nausea and vomiting prevention, especially in oncology supportive care.
• Helsinn Healthcare and partners — Products such as Aloxi and Akynzeo compete in chemotherapy-induced nausea and vomiting management and are important branded reference points in oncology supportive care.
• Generic injectable manufacturers including Fresenius Kabi, Hikma, Pfizer/Hospira, Teva, Sandoz, and Dr. Reddy’s — In practice, generics are often Heron’s most persistent competitors because hospitals and clinics compare branded products against lower-cost antiemetics, anesthetics, and multimodal regimens.
• Procedure-based substitutes and protocol alternatives — For ZYNRELEF, alternatives such as standard local anesthetics, nerve blocks, and multimodal pain regimens compete for the same clinical objective. For Heron’s antiemetics, established combination regimens can also limit branded uptake.

From a business-model perspective, Pacira is probably the closest peer because both companies rely on specialized hospital selling, formulary access, and clinical-protocol adoption rather than broad retail prescription volume.

6. What Is the Marketing Strategy of Heron Therapeutics?

Heron’s marketing strategy is targeted, clinical, and account-based. This is not a consumer-brand business. The company markets mainly to surgeons, anesthesiologists, perioperative leaders, oncology clinicians, oncology pharmacists, and hospital pharmacy or value-analysis committees.

In acute care, marketing appears to focus on procedure-level education, formulary support, and the economic and clinical case for using branded products inside perioperative protocols. In oncology, marketing is more regimen- and account-oriented, with emphasis on antiemetic performance, convenience, and fit within established supportive-care pathways. Conference presence, peer-to-peer education, medical affairs support, and reimbursement messaging are likely more important than mass advertising.

Brand marketing matters, but mainly as a supporting capability. The real differentiator is whether Heron can combine clinical evidence, account targeting, and access support well enough to change provider behavior in settings that already have entrenched generic options.

7. What Are the Key Customer Segments of Heron Therapeutics?

• Large pharmaceutical wholesalers and specialty distributors: These are often Heron’s direct purchasing customers and create channel concentration, even though they are not the ultimate clinical decision-makers.
• Hospitals and health systems: These accounts matter for acute care products and some oncology use. Decision-making often involves pharmacy, anesthesia, surgery, nursing, and value-analysis stakeholders.
• Ambulatory surgery centers: These are increasingly important for acute care because they value efficient perioperative protocols, predictable recovery pathways, and reimbursement clarity.
• Community oncology clinics and hospital infusion centers: These are the core end markets for CINVANTI and SUSTOL, especially under buy-and-bill dynamics.
• Payers and reimbursement authorities: They are not direct purchasers in the same way providers are, but reimbursement policy strongly affects utilization and economics.

Heron is diversified across two clinical franchises, but it is not broadly diversified across customer types or geographies. Its business remains dependent on a relatively small set of U.S. provider channels and a limited number of wholesale customers.

8. What Is the Sales Model of Heron Therapeutics?

Heron uses a specialty pharmaceutical sales model built around direct field selling plus wholesale distribution.

1. Heron contracts with wholesalers and distributors to move product into provider channels.
2. A direct specialty sales force calls on target accounts such as hospitals, ambulatory surgery centers, oncology clinics, and related clinical stakeholders.
3. Products must often win formulary or protocol approval before broad utilization begins, especially in hospital settings.
4. Utilization then depends on repeat clinical use in procedures or infusion regimens rather than on patient self-directed demand.

This channel structure has major implications. Growth can be sticky once an account adopts a product into routine use, but the initial sales cycle is slower and more consultative than in retail pharma. Pricing is also constrained by GPO contracting, wholesaler economics, and reimbursement. For consultants, that means sales productivity, territory design, account prioritization, and access strategy can all have an outsized effect on results.

9. In What Geographies Does Heron Therapeutics Operate?

Heron’s commercial business is primarily U.S.-focused. The company’s headquarters are in Cary, North Carolina, and it has historically maintained operations in San Diego, California. Its marketed products are aimed mainly at U.S. hospitals, ambulatory surgery centers, and oncology clinics.

Heron does not appear to have the broad multinational commercial footprint of large pharmaceutical companies. Any ex-U.S. activity appears secondary to the core U.S. business. That makes the company strategically concentrated: U.S. procedure volume, U.S. oncology utilization, U.S. reimbursement conditions, and U.S. wholesaler relationships matter far more to Heron than international diversification.

Operationally, the company relies on third-party manufacturers and logistics providers rather than a disclosed global network of company-owned plants and depots.

10. Who Are the Owners of Heron Therapeutics?

Heron is a publicly traded company listed on Nasdaq under HRTX. As reflected in recent proxy materials and public ownership filings in 2025, Heron does not appear to have a controlling shareholder. Ownership is primarily institutional and retail, with large asset managers and healthcare-focused investment funds represented in the shareholder base.

11. How Is Heron Therapeutics Organized?

Heron appears to be organized as a focused commercial-stage biopharma company with one reportable segment. It is not a diversified holding company.

Practically, the business is managed around two commercial franchises:

• Acute Care — led by ZYNRELEF and APONVIE, with selling concentrated in perioperative and surgical settings.
• Oncology Care — led by CINVANTI and SUSTOL, with commercial activity centered on oncology clinics and infusion centers.

Supporting functions likely include regulatory affairs, medical affairs, quality, manufacturing and supply-chain management, market access, finance, compliance, and corporate administration. That structure is typical for a specialty-pharma company whose main challenge is executing a small portfolio efficiently rather than managing many unrelated business lines.

12. How Does Heron Therapeutics Operate?

On a day-to-day basis, Heron operates as an outsourced-manufacturing, specialty-commercialization company.

1. Product planning and demand forecasting: Heron forecasts demand by product, account, and channel, which is important because the portfolio is relatively concentrated and stockouts could damage adoption.
2. Third-party manufacturing oversight: The company relies on external partners for key production steps, so supplier management, quality control, and batch release are central operating tasks.
3. Distribution into provider channels: Finished goods move through wholesalers, distributors, and logistics partners into hospitals, surgery centers, and oncology practices.
4. Commercial execution: Sales teams work to gain formulary access, support protocol adoption, and increase account utilization.
5. Medical, regulatory, and safety management: Like any marketed pharmaceutical company, Heron must maintain pharmacovigilance, compliance, and regulatory support for its products.

The main operational complexities are not consumer marketing or large-scale internal manufacturing; they are account conversion, reimbursement support, supply reliability, and consistent execution across a small number of strategically important brands.

13. What Are the Growth Opportunities for Heron Therapeutics?

• Broader ZYNRELEF penetration: The most obvious growth opportunity is deeper use of ZYNRELEF across targeted surgical procedures, hospitals, and ambulatory surgery centers. Management’s messaging suggests that increasing utilization within existing accounts is at least as important as adding new accounts.
• Cross-selling APONVIE into the same acute care accounts: Because APONVIE and ZYNRELEF share perioperative customers, Heron has an opportunity to improve sales-force productivity and strengthen the value of its acute care portfolio.
• Protocol-based acute care bundles: An attractive strategic opportunity is to position pain management and nausea prevention together in perioperative pathways. This is a logical extension of Heron’s portfolio, even if adoption ultimately depends on account-specific economics.
• Stabilizing and selectively growing the oncology franchise: CINVANTI and SUSTOL may offer additional growth from account execution, regimen positioning, and retention, even if these are more mature products than the acute care brands.
• Lifecycle management and evidence generation: Additional studies, real-world data, and label-supporting work can improve adoption if they strengthen the health-economic or clinical case for use.
• Adjacent business development: A reasonable external inference is that Heron could benefit from adding adjacent acute care or supportive-care assets that fit the same call points, provided capital discipline is maintained.

The main constraints are familiar: entrenched generic alternatives, the difficulty of changing clinical behavior, limited geographic diversification, dependence on a small number of products, and the need to maintain reliable supply while preserving margins.

14. What Is the History of Heron Therapeutics?

• 1983: The company was founded and later operated for many years as A.P. Pharma.
• 2014: The company changed its name to Heron Therapeutics, reflecting a broader specialty-pharma identity.
• 2016: Heron received FDA approval for SUSTOL, an important step in becoming a commercial oncology supportive-care company.
• 2017: FDA approval of CINVANTI expanded the oncology franchise and strengthened Heron’s antiemetic portfolio.
• 2021: FDA approval of ZYNRELEF moved the company more meaningfully into acute care and perioperative pain management.
• 2023: FDA approval of APONVIE added another perioperative product and increased the strategic coherence of the acute care portfolio.
• FY2024 and beyond: Heron’s story increasingly shifted from product approval toward commercial scale, account execution, and profitability discipline.

Overall, Heron’s history is best understood as a transition from development-stage biotech to a small but commercial specialty-pharma company with a focused hospital and oncology footprint.

15. What Are the Key Suppliers to Heron Therapeutics?

Suppliers matter strategically to Heron because the company relies heavily on outsourced manufacturing and does not have the diversified internal production base of large pharma.

• Active pharmaceutical ingredient suppliers: Suppliers of ingredients such as bupivacaine, meloxicam, aprepitant, granisetron, and related excipients are foundational to continuity of supply.
• Contract manufacturing organizations: Third-party manufacturers handle important production steps for sterile injectables, extended-release formulations, and fill-finish activities.
• Packaging, testing, and release partners: Analytical testing labs, packagers, and quality-service providers help move batches into commercial distribution.
• Third-party logistics providers: Warehousing and physical distribution partners are necessary to maintain reliable service into provider channels.

Specific supplier names are not widely emphasized in public materials, but the strategic issue is clear: limited-source or single-source dependencies can affect revenue, gross margin, and account credibility if supply is interrupted.

16. What Are the Key Brands Owned by Heron Therapeutics?

Branding matters at Heron, but mostly in a clinical and formulary context rather than a consumer one. The core brands are the products themselves.

• ZYNRELEF — Positioned as a differentiated postsurgical analgesia brand in acute care. It is central to Heron’s non-opioid pain-management narrative and likely the most strategically important growth brand.
• APONVIE — Positioned in perioperative nausea and vomiting prevention. Its importance comes partly from sharing call points with ZYNRELEF, making it a portfolio-strengthening brand.
• CINVANTI — A core oncology supportive-care brand with established relevance in chemotherapy-induced nausea and vomiting management.
• SUSTOL — A mature oncology supportive-care brand that complements CINVANTI and broadens Heron’s antiemetic offering.

For Heron, strong branding helps with recognition and positioning, but formulary access, clinical evidence, and reimbursement usually matter more than consumer-style brand equity.

17. How Does the Supply Chain of Heron Therapeutics Function?

Heron’s supply chain is typical of an outsourced specialty-pharma model but strategically important because the company has a concentrated portfolio.

1. Sourcing: Heron procures active ingredients, excipients, and specialized materials through external suppliers.
2. Manufacturing: Contract manufacturers produce and fill finished dosage forms, including sterile and extended-release products.
3. Quality and release: Batches must pass testing, quality review, and regulatory controls before commercial distribution.
4. Warehousing and logistics: Product moves through third-party logistics networks into wholesalers and specialty distributors.
5. Provider delivery: Wholesalers and distributors supply hospitals, ambulatory surgery centers, and oncology practices.

Supply-chain performance matters because stockouts can slow protocol adoption, while excess inventory can pressure working capital and increase write-off risk. Lead times, quality reliability, and coordination with commercial demand are therefore central to execution.

18. What Is the R&D Strategy of Heron Therapeutics?

Heron’s R&D strategy appears more focused and pragmatic than that of a discovery-driven biotech. The company’s historical strength has been formulation and delivery innovation applied to well-understood therapeutic needs, rather than broad early-stage target discovery.

That pattern is visible across the commercial portfolio. ZYNRELEF reflects formulation-driven differentiation in postsurgical analgesia, while CINVANTI and APONVIE are differentiated aprepitant injectable emulsions and SUSTOL is an extended-release antiemetic formulation. As of FY2024 and early 2025, public evidence suggests that Heron’s R&D emphasis is on lifecycle management, supporting evidence generation, and selective product-development work that is closely tied to commercial relevance.

In practical terms, that means R&D at Heron is likely judged less by the size of an early-stage pipeline and more by whether it can improve adoption, expand use cases, or reinforce the value proposition of existing brands.

19. What Is the Finance Strategy of Heron Therapeutics?

Heron’s finance strategy, as reflected in FY2024 and 2025 communications, appears centered on turning a small commercial portfolio into a more self-sustaining business.

• Prioritize operating leverage: A core objective is to spread commercial and corporate overhead across a growing revenue base, especially by using one infrastructure across multiple products.
• Manage cash carefully: As a smaller specialty-pharma company, Heron must balance investment in sales execution, inventory, and medical support against liquidity discipline.
• Focus on profitable growth rather than growth at any cost: Management messaging has emphasized both revenue growth and adjusted EBITDA improvement, which is an important distinction from earlier-stage biotech models that prioritize pipeline expansion regardless of current earnings.
• Control gross-to-net and working capital: Realized revenue depends on rebates, discounts, chargebacks, and returns, so finance execution matters beyond simple unit growth.
• Reinvest rather than return capital: Heron is not a dividend or buyback story. Capital allocation is better understood as commercial reinvestment, supply support, and selective product development.

For investors and operators alike, the financial question is whether Heron can keep expanding sales from a concentrated portfolio while preserving enough margin and cash flexibility to avoid returning to a more capital-dependent biotech posture.

20. How Companies Like Heron Therapeutics Leverage Independent Consultants through Umbrex

Heron-sized specialty-pharma companies often need highly experienced consulting talent for targeted initiatives, but they do not always need a full traditional consulting team. Umbrex has grown a global community of more than 8,000 independent management consultants based in more than 50 countries. These consultants are alumni of McKinsey, Bain, BCG, and other top firms, and they work across strategy, operations, organization, marketing, sales, finance, technology, ERP, and AI. For a company like Heron Therapeutics, that model is especially relevant when management needs sharp, project-based support tied to commercial execution, supply reliability, or portfolio strategy.

• Procedure-level market sizing and account segmentation for ZYNRELEF adoption across hospitals and ambulatory surgery centers
• Acute care sales-force territory design, call-plan optimization, and rep productivity benchmarking for ZYNRELEF and APONVIE
• Hospital formulary and protocol-adoption strategy, including value-analysis committee messaging and account-conversion playbooks
• Gross-to-net, pricing, and contracting analytics across wholesalers, GPOs, and buy-and-bill channels
• Oncology franchise retention and growth strategy for CINVANTI and SUSTOL, including account prioritization and regimen-level opportunity mapping
• Demand forecasting, sales and operations planning, and inventory optimization for an outsourced manufacturing network
• Supply-risk assessment and resilience planning for limited-source suppliers and contract manufacturing dependencies
• Commercial excellence reviews linking CRM data, ordering patterns, and field activity to repeat usage by account and procedure type
• Business development screening for adjacent acute care or supportive-care assets that fit Heron’s existing call points
• AI-enabled dashboards for demand sensing, account prioritization, and sales-management reporting without building a large internal analytics team